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Patrick O’Gara, MD, FACC, ACC PresidentA number of new clinical trials released overthe last few months have caused both phy-sicians and the media to raise questions
about the need to change current clinical practice
guideline (CPG) recommendations. Answers to these
questions must reﬂect back on the careful and
collaborative methods by which the American
College of Cardiology (ACC) authors its CPGs in
partnership with the American Heart Associa-
tion (AHA) and other professional organizations.
Although well-conceived and executed trials add
to the totality of evidence upon which recommen-
dations can be made, whether any single trial can
or should alter a diagnostic or treatment recom-
mendation must be considered deliberately and
often at a time removed from the initial trial
release. Experts must weigh the quality of the evi-
dence and dispassionately debate the merits of any
trial, balancing the desire to speed new or improved
therapies into practice against any associated risks,
some of which are not often apparent on initial
review.
One of the biggest new trials—the PARADIGM-HF
(Multicenter, Randomized, Double-blind, Parallel
Group, Active-controlled Study to Evaluate the Ef-
ﬁcacy and Safety of LCZ696 Compared to Enala-
pril on Morbidity and Mortality in Patients With
Chronic Heart Failure and Reduced Ejection Frac-
tion) trial—generated the most buzz about the
future of heart failure treatment during the 2014
European Society of Cardiology (ESC) Congress in
Barcelona, Spain. The study, which compared theCardiology, Washington, DC.combination angiotensin receptor-neprilysin inhibi-
tor LCZ696, an investigational new heart failure
drug, with enalapril in patients with heart failure
and reduced ejection fraction, was stopped early
because of overwhelming beneﬁt with LCZ696.
At a mean of 27 months follow-up, the primary
outcome of cardiovascular death and hospitali-
zation for heart failure had occurred in 21.8% of
patients in the LCZ696 group versus 26.5% in
the enalapril group (hazard ratio: 0.80, 95% conﬁ-
dence interval: 0.73 to 0.87, p < 0.001). In addition,
LCZ696 signiﬁcantly reduced the incidence of the
individual endpoints of total death, cardiovascular
death, and hospitalization for heart failure, and
decreased the symptoms and physical limitations of
heart failure (1).
Results from the CvLPRIT (Complete Versus
Lesion Only PRimary-PCI Trial), also released at
the 2014 ESC Congress, found that patients with
ST-segment elevation myocardial infarction (STEMI)
undergoing complete revascularization had better
outcomes and experienced fewer major adverse
cardiac events compared with those who had only
“culprit” artery revascularization (2). These results
reinforce data from another trial, PRAMI (Preventive
Angioplasty in Myocardial Infarction), published in
2013, which showed percutaneous coronary inter-
vention (PCI) of all coronary arteries with major
stenoses (i.e., >50% angiographic narrowing) may
improve outcomes (3). Although questions remain
about the exact timing of nonculprit artery PCI (i.e.,
at the time of primary PCI or later during the index
hospitalization), whether certain patients beneﬁt
versus others, whether fractional ﬂow reserve might
guide decisions, and the role of patient complexity
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enough concern that the College has recently with-
drawn its recommendation that nonculprit artery
PCI not be performed at the time of primary PCI
from the Foundation’s Choosing Wisely campaign
until the issue can be settled. The ACC is working
with the AHA and its other partners on the guide-
lines for management of patients with STEMI to
address these ﬁndings. Changes to the PCI guide-
lines and appropriate use criteria for revasculariza-
tion are also under advisement.
The 1-year results of a third trial that may
alter clinical practice was also reported at ESC 2014.
In the TASTE (Thrombus Aspiration in ST-Elevation
Myocardial Infarction in Scandinavia) trial, in-
vestigators assessed the beneﬁt of routine thrombus
aspiration at the time of primary PCI for STEMI
patients (4). In contrast to a previous study, they
reported no survival beneﬁt with routine thrombus
aspiration or any reduction in a combined endpoint of
death, rehospitalization for myocardial infarction, or
stent thrombosis.
These and other trials underscore the fact that
science is not static, but is rather constantly evolving.
The College and others need to be responsive to these
dynamic changes and ensure that cardiovascular
professionals are providing the most appropriate,
evidence-based care. However, there is also a need to
maintain the rigorous processes and methodologies
associated with CPG development.
This year marks the 30th anniversary of joint
ACC/AHA CPG development. This collaborative
effort began in response to the U.S. government’s
request to review the evidence concerning cardiac
pacemakers and develop guidelines to limit poten-
tial overuse. Since then, there have been 23 guide-
lines developed across a broad spectrum of
cardiovascular diseases and procedures. In a recent
report on this 30-year partnership, Jacobs et al. (5)
point out that balancing the constant release of
new evidence with guideline development and up-
dates is an ongoing challenge. “Although the de-
livery of timely CPGs is essential,” they write, “it is
also important to balance speed with deliberation
and accuracy and to allow new treatments to
adequately dwell in the clinical arena to assess
generalizability and long-term outcomes in clinical
practice” (5).
Over the last several years, the ACC/AHA Task
Force on CPGs has made several changes to guide-
line development to better navigate through such
changing times; for example, by adding formal evi-
dence reviews, expanding the peer-review process,and updating the guideline writing committee se-
lection process to account for the need to include
trained methodologists and health economists, as
well as to abide by both organizations’ relationships
with industry policies. The recent guidelines process
report notes that creation of ongoing “living” docu-
ments is under development on various digital
platforms (5).
There are also efforts under way to embed guide-
line recommendations and prompts within electronic
health record systems and mobile devices. The
ACC/AHA ASCVD Risk Estimator mobile application
released earlier this year in conjunction with the new
prevention guidelines is just 1 example of how we are
working to make recommendations accessible at
the point of care. The College is also excited to
pilot its Guideline Clinical Apps intended to
quickly disseminate information on 5 speciﬁc guide-
lines: management of atrial ﬁbrillation, treatment of
blood cholesterol, assessment of CV risk, manage-
ment of heart failure, and management of valvular
heart disease. The app will also deliver interactive
guideline-related tools and provide point-of-care
support.
Moving ahead, the ACC will need to pay
continued attention to just how, and how quickly,
we can and should implement changes to the
guidelines, as well as to develop tools to make these
guidelines accessible at the point of care. We would
be remiss if we didn’t factor in cost and value,
as well as look closely at what level and quality
of evidence triggers the development of new or
updating of old recommendations. There are also
increasing opportunities to work together to har-
monize guideline recommendations with our inter-
national colleagues, particularly the ESC (6). Such
harmonization could reduce confusion about rec-
ommendations across borders, minimize duplication,
and perhaps streamline future guideline develop-
ment efforts across the global community in which
we work.
At the end of the day, our fundamental commit-
ment to providing cardiovascular professionals with
the best guidance on how to ensure the most appro-
priate and cost-effective care to cardiovascular
patients will remain unchanged. Patients, clinicians,
payers, lawmakers, and other stakeholders look for us
to lead in this area, and we will continue to do so with
our partners.
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